Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion.

backgroundBaicalin is the main bioactive constitute of the dried roots of

objectiveThe present study was conducted to enhance the dissolution and oral bioavailability of baicalin (BA) through a novel mesoporous carbon nanopowder (MCN) drug carrier. MATERIALS AND

methodsSolid dispersions (SDs) of BA with MCN were prepared using a solvent evaporation method. The physical state of the formulations was investigated using SEM, differential scanning calorimetry (DSC) and powder X-ray diffraction (XRD). The pharmaceutical performance of pure BA, physical mixture (PM) and SDs was evaluated by performing an

resultsThe drug release profile indicated that the BA dissolution rate from SDs with a BA/MCN ratio of 1:6 greatly increased in comparison with that of the pure crystalline drug. Furthermore, a pharmacokinetic analysis in rats showed that the BA area under the concentration-time curve for SDs of MCN/BA was 1.83 times larger than that of pure BA. In comparison with the pure drug, the MCN-BA system significantly shortened the time to

conclusionThese results indicated that the oral bioavailability of BA was remarkably improved by the MCN carrier. Additionally, intestinal toxicity test showed that MCN produced no toxicity in the gastrointestinal tract. Our results show that MCN-based SDs could be used to enhance the bioavailability of drugs with poor water solubility. SUMMARY: The drug release profile indicated that the BA dissolution rate from SDs with a BA/MCN ratio of 1:6 greatly increased in comparison with that of the pure crystalline drug.Furthermore, a pharmacokinetic analysis in rats showed that the BA area under the concentration-time curve for SDs of MCN/BA was 1.83 times larger than that of pure BA.In comparison with the pure drug, the MCN-BA system significantly shortened the time to